Monoclonal Anti-AP2 (mouse IgG1 isotype) is derived from the hybridoma A6/2/2 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a peptide corresponding to amino acids of human AP2a. In humans and mice, the adaptor protein-2 (AP2) family comprises five different transcription factors namely AP2a, AP2ß, AP2 ?, AP2d, and AP2e. These proteins contain N-terminal transactivation domain and C-terminal helix-span-helix motif, which together with a central basic region facilitates dimerization and DNA binding.
Synonyms: Anti-AP2TF; Anti-TFAP2
Storage: -20C
Application: Monoclonal Anti-AP2 antibody produced in mouse has been used in:
•immunofluorescence staining
•immunoblotting
•immunohistochemistry
Biochem Physiol Actions: Adaptor protein-2 (AP2) expression is associated with the embryonic development. AP2ß was found to be a tumor specific human telomerase reverse transcriptase (hTERT) promoter activator, suggesting it may be a biomarker for cancer diagnosis or as a cancer therapeutic target for inhibiting hTERT activity and tumor cell growth. In humans, mutations or loss of these genes result in increased tumor growth and metastasis. Specifically, AP2a loss causes down regulation of E-cadherin and matrix metallopeptidase 9 (MMP-9) activity, which in turn enhance tumorigenicity of colon cancer cells. This effect may also be the result of AP2a regulation by p53.